Therefore, GLI1 inhibitor may potentially be added to other redifferentiation strategies to overcome therapeutic resistance or to obtain synergistic effects in RAI-refractory thyroid cancers. This evidence concerns the gene GLI1 and thyroid gland carcinoma.